Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT · References

References

CC BY 4.0 · NIHR Journals Library · approximately 10 min read

  1. Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg 2018;1:1–18. 10.3171/2017.10.JNS17352
  2. Peden N, Scurfield R, Sleet D, Mohan D, Hyder AA, Jarawan E, Mathers C. World Report on Road Traffic Injury Prevention. Geneva: World Health Organization; 2004.
  3. Haydel M. Assessment of Traumatic Brain Injury, Acute. BMJ Best Practice; 2018. URL: https://bestpractice.bmj.com/topics/en-gb/515 (accessed 28 November 2019).
  4. Perel P, Roberts I, Bouamra O, Woodford M, Mooney J, Lecky F. Intracranial bleeding in patients with traumatic brain injury: a prognostic study. BMC Emerg Med 2009;9:15. 10.1186/1471-227X-9-1519650902
  5. Oertel M, Kelly DF, McArthur D, Boscardin WJ, Glenn TC, Lee JH, et al. Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg 2002;96:109–16. 10.3171/jns.2002.96.1.010911794591
  6. Narayan RK, Maas AI, Servadei F, Skolnick BE, Tillinger MN, Marshall LF, Traumatic Intracerebral Hemorrhage Study Group. Progression of traumatic intracerebral hemorrhage: a prospective observational study. J Neurotrauma 2008;25:629–39. 10.1089/neu.2007.038518491950
  7. Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005;365:1957–9. 10.1016/S0140-6736(05)66552-X15936423
  8. Rodríguez-Boto G, Rivero-Garvía M, Gutiérrez-González R, Márquez-Rivas J. Basic concepts about brain pathophysiology and intracranial pressure monitoring. Neurologia 2015;30:16–22. 10.1016/j.nrl.2012.09.00223246212
  9. Carney N, Totten AM, O’Reilly C, Ullman JS, Hawryluk GW, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery 2017;80:6–15. 10.1227/NEU.000000000000143227654000
  10. Harhangi BS, Kompanje EJ, Leebeek FW, Maas AI. Coagulation disorders after traumatic brain injury. Acta Neurochir (Wien) 2008;150:165–75. 10.1007/s00701-007-1475-818166989
  11. Bayir A, Kalkan E, Koçak S, Ak A, Cander B, Bodur S. Fibrinolytic markers and neurologic outcome in traumatic brain injury. Neurol India 2006;54:363–5. 10.4103/0028-3886.2810617114843
  12. Gebel JM, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S, et al. Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002;33:2636–41. 10.1161/01.str.0000035283.34109.ea12411654
  13. Figueroa BE, Keep RF, Betz AL, Hoff JT. Plasminogen activators potentiate thrombin-induced brain injury. Stroke 1998;29:1202–7. 10.1161/01.str.29.6.12029626295
  14. Thiex R, Küker W, Müller HD, Rohde I, Schröder JM, Gilsbach JM, Rohde V. The long-term effect of recombinant tissue-plasminogen-activator (rt-PA) on edema formation in a large-animal model of intracerebral hemorrhage. Neurol Res 2003;25:254–62. 10.1179/01616410310120146312739233
  15. Thiex R, Mayfrank L, Rohde V, Gilsbach JM, Tsirka SA. The role of endogenous versus exogenous tPA on edema formation in murine ICH. Exp Neurol 2004;189:25–32. 10.1016/j.expneurol.2004.05.02115296833
  16. Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, Ker K. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011;1:CD001886. 10.1002/14651858.CD001886.pub3
  17. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23–32. 10.1016/S0140-6736(10)60835-520554319
  18. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011;377:1096–101, 1101.e1–2. 10.1016/S0140-6736(11)60278-X
  19. Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I, Antifibrinolytic Trials Collaboration. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40138 bleeding patients. Lancet 2018;391:125–32. 10.1016/S0140-6736(17)32455-829126600
  20. Crash-2 Collaborators (Intracranial Bleeding Study). Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ 2011;343:d3795. 10.1136/bmj.d379521724564
  21. Yutthakasemsunt S, Kittiwatanagul W, Piyavechvirat P, Thinkamrop B, Phuenpathom N, Lumbiganon P. Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial. BMC Emerg Med 2013;13:20. 10.1186/1471-227X-13-2024267513
  22. Dewan Y, Komolafe EO, Mejía-Mantilla JH, Perel P, Roberts I, Shakur H, CRASH-3 Collaborators. CRASH-3 – tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials 2012;13:87. 10.1186/1745-6215-13-8722721545
  23. Roberts I, Belli A, Brenner A, Chaudhri R, Fawole B, Harris T. Tranexamic acid for significant traumatic brain injury (The CRASH-3 trial): Statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. Wellcome Open Res 2018;3:86 10.12688/wellcomeopenres.14700.230175246
  24. The CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019:394;1713–23. 10.1016/S0140-6736(19)32233-031623894
  25. Weijer C, Shapiro SH, Cranley Glass K. For and against: clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. BMJ 2000;321:756–8. 10.1136/bmj.321.7263.75610999914
  26. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191–4. 10.1001/jama.2013.28105324141714
  27. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose–response relationship of tranexamic acid. Anesthesiology 1995;82:383–92. 10.1097/00000542-199502000-000097856897
  28. Rappaport M, Hall KM, Hopkins K, Belleza T, Cope DN. Disability rating scale for severe head trauma: coma to community. Arch Phys Med Rehabil 1982;63:118–23. 10.1037/t29015-0007073452
  29. Electronic Medicines Compendium. Tranexamic Acid 100 mg/ml Solution for Injection. 2018. URL: www.medicines.org.uk/emc/product/1220/smpc#gref (accessed 28 November 2019).
  30. Hijazi N, Abu Fanne R, Abramovitch R, Yarovoi S, Higazi M, Abdeen S, et al. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood 2015;125:2558–67. 10.1182/blood-2014-08-58844225673638
  31. Medcalf RL. The traumatic side of fibrinolysis. Blood 2015;125:2457–8. 10.1182/blood-2015-02-62980825883229
  32. Barton BL. International conference on harmonization-good clinical practices update. Drug Inf J 1998;32:1143–7. 10.1177/00928615980320043410
  33. Chapman MP, Moore EE, Moore HB, Gonzalez E, Gamboni F, Chandleret JG, et al. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg 2016;80:16–23. 10.1097/TA.000000000000088526491796
  34. Wu X, Darlington DN, Cap AP. Procoagulant and fibrinolytic activity after polytrauma in rat. Am J Physiol Regul Integr Comp Physiol 2016;310:R323–9. 10.1152/ajpregu.00401.201526632604
  35. Roberts I, Prieto-Merino D, Manno D. Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. Crit Care 2014;18:685. 10.1186/s13054-014-0685-825498484
  36. Moore EE, Moore HB, Gonzalez E, Chapman MP, Hansen KC, Sauaia A, et al. Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid. J Trauma Acute Care Surg 2015;78(Suppl. 6):65–9. 10.1097/TA.0000000000000634
  37. Epstein DS, Mitra B, O’Reilly G, Rosenfeld JV, Cameron PA. Acute traumatic coagulopathy in the setting of isolated traumatic brain injury: a systematic review and meta-analysis. Injury 2014;45:819–24. 10.1016/j.injury.2014.01.01124529718
  38. Abdelmalik PA, Boorman DW, Tracy J, Jallo J, Rincon F. Acute traumatic coagulopathy accompanying isolated traumatic brain injury is associated with worse long-term functional and cognitive outcomes. Neurocrit Care 2016;24:361–70. 10.1007/s12028-015-0191-026293923
  39. Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004;364:1321–8. 10.1016/S0140-6736(04)17188-215474134
  40. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013 (PMG9). London: NICE; 2013.
  41. Williams J, Roberts I, Shakur-Still H, Lecky FE, Chaudhri R, Miners A. Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach. BMJ Global Health 2020;5:e002716. 10.1136/bmjgh-2020-002716
  42. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 2013;346:f1049. 10.1046/j.1365-2958.2001.02411.x23529982
  43. McMillan TM, Teasdale GM, Weir CJ, Stewart E. Death after head injury: the 13 year outcome of a case control study. J Neurol Neurosurg Psychiatry 2011;82:931–5. 10.1136/jnnp.2010.22223221282727
  44. Office for National Statistics. National Life Tables: UK. 2016–2018. 2019. URL: www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables (accessed 30 October 2019).
  45. Ward Fuller G, Hernandez M, Pallot D, Lecky F, Stevenson M, Gabbe B. Health state preference weights for the Glasgow Outcome Scale following traumatic brain injury: a systematic review and mapping study. Value Health 2017;20:141–51. 10.1016/j.jval.2016.09.239828212955
  46. Teasdale G, Maas A, Lecky F, Manley G, Stocchetti N, Murray G. The Glasgow Coma Scale at 40 years: standing the test of time. Lancet Neurol 2014;13:844–54. 10.1016/S1474-4422(14)70120-625030516
  47. Born K, Amsler F, Gross T. Prospective evaluation of the Quality of Life after Brain Injury (QOLIBRI) score: minor differences in patients with major versus no or mild traumatic brain injury at one-year follow up. Health Qual Life Outcomes 2018;16:136. 10.1186/s12955-018-0966-z29986710
  48. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. York: Centre for Health Economics, University of York; 1999.
  49. Joint Formulary Committee. British National Formulary. Sodium Chloride. Ed 77. London: BMJ Group and Pharmaceutical Press; 2019.
  50. National Institute for Health and Care Excellence (NICE). Costing Statement: Needle and Syringe Programmes. London: NICE; 2014.
  51. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I, CRASH 2 trial collaborators. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLOS ONE 2011;6:e18987. 10.1371/journal.pone.001898721559279
  52. Curtis L, Burns A. Unit Costs of Health and Social Care 2018. Canterbury: Personal Social Services Research Unit, University of Kent; 2018.
  53. Department of Health and Social Care (DHSC). NHS Reference Costs 2017–18. London: DHSC; 2018.
  54. Beecham J, Perkins M, Snell T, Knapp M. Treatment paths and costs for young adults with acquired brain injury in the United Kingdom. Brain Inj 2009;23:30–8. 10.1080/0269905080259033819096972
  55. Lecky F, Russell W, Fuller G, McClelland G, Pennington E, Goodacre S, et al. The Head Injury Transportation Straight to Neurosurgery (HITS-NS) randomised trial: a feasibility study. Health Technol Assess 2016;20(1). 10.3310/hta20010
  56. Joint Formulary Committee. British National Formulary (online). Tranexamic Acid. London: BMJ Group and Pharmaceutical Press. URL: https://bnf.nice.org.uk/medicinal-forms/tranexamic-acid.html; 2019 (accessed 24 September 2019).
  57. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. URL: https://bnf.nice.org.uk/medicinal-forms/sodium-chloride.html; 2019 (accessed 24 September 2019).
  58. May S. Prehospital Tranexamic Acid Use for Traumatic Brain Injury (TXA). URL: https://clinicaltrials.gov/ct2/show/NCT01990768 (accessed 19 November 2019).
  59. Rodgers A, MacMahon S. Systematic underestimation of treatment effects as a result of diagnostic test inaccuracy: implications for the interpretation and design of thromboprophylaxis trials. Thromb Haemost 1995;73:167–71. 10.1055/s-0038-16537467792725
  60. National Institute for Health and Care Excellence (NICE). Trauma Quality Standard (QS166). London: NICE; 2018.
  61. Mahmood A, Roberts I, Shakur H, Harris T, Belli A. Does tranexamic acid improve outcomes in traumatic brain injury? BMJ 2016;354:i4814. 10.1136/bmj.i481427682806
  62. Perel P, Al-Shahi Salman R, Kawahara T, Morris Z, Prieto-Merino D. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury – a nested randomised, placebo-controlled trial. Health Technol Assess 2012;16(13). 10.3310/hta16130
  63. Joint Royal Colleges Ambulance Liaison Committee, Association of Ambulance Chief Executives. JRCALC Clinical Guidelines 2019. Bridgwater: Class Professional Publishing; 2019.
  64. National Institute for Health and Care Excellence (NICE). Head Injury: Assessment and Early Management. London: NICE; 2019.
  65. Coats TJ, Fragoso-Iñiguez M, Roberts I. Implementation of tranexamic acid for bleeding trauma patients: a longitudinal and cross-sectional study. Emerg Med J 2019;36:78–81. 10.1136/emermed-2018-20769330530744
  66. Wright C. Battlefield administration of tranexamic acid by combat troops: a feasibility analysis. J R Army Med Corps 2014;160:271–2. 10.1136/jramc-2013-00015224155347
  67. Carley S, Mackway-Jones K, Donnan S. Major incidents in Britain over the past 28 years: the case for the centralised reporting of major incidents. J Epidemiol Community Health 1998;52:392–8. 10.1136/jech.52.6.3929764261
  68. Puigdellívol E, Carral ME, Moreno J, Plà-Delfina JM, Jané F. Pharmacokinetics and absolute bioavailability of intramuscular tranexamic acid in man. Int J Clin Pharmacol Ther Toxicol 1985;23:298–301.4018929
  69. Sano M, Hakusui H, Kojima C, Akimoto T. Absorption and excretion of tranexamic acid following intravenous, intramuscular and oral administrations in healthy volunteers. Rinsho yakuri/Japanese J Clin Pharmacol Ther 1976;7:375–82. 10.3999/jscpt.7.375
  70. Haljamäe H. Microcirculation and hemorrhagic shock. Am J Emerg Med 1984;2:100–7. 10.1016/0735-6757(84)90117-76517978
  71. Yost J, Baldwin P, Bellenger S, Bradshaw F, Causapin E, Demotica R, et al. The pharmacokinetics of intraosseous atropine in hypovolemic swine. Am J Disaster Med 2015;10:217–22. 10.5055/ajdm.2015.020426663305
  72. First Release of CRASH-3 Trial Results. Conference Presentation. Presented by Ian Roberts. World Congress of Intensive Care 2019, Melbourne, VIC, 15 October 2019.
  73. Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-controlled Trial. Conference Presentation. Presented by Haleema Shakur-Still 17th Annual Meeting Neurocritical Care Society, Vancouver, BC, 16 October 2019.
  74. World Health Organization (WHO). WHO Model List of Essential Medicines. Geneva: WHO; 2019.
  75. Guthrie S, Hafner M, Bienkowska-Gibbs T, Wooding S. Returns on research funded under the NIHR Health Technology Assessment (HTA) programme. Rand Health Q 2016;5:5.
  76. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Arch Surg 2012;147:113–19. 10.1001/archsurg.2011.28722006852
  77. European Council. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. 2001. URL: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf (accessed 20 November 2020).
  78. Perel P, Arango M, Clayton T, Edwards P, Komolafe E, Poccock S, et al. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ 2008;336:425–9. 10.1136/bmj.39461.643438.2518270239
← Reflections and concluding remarksAcknowledgements →

Attribution. Ian Roberts; Haleema Shakur-Still; Amy Aeron-Thomas; Danielle Beaumont; Antonio Belli; Amy Brenner et al. (2021). Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT. NIHR Journals Library. Copyright © 2021 Roberts et al. This work was produced by Roberts et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited. Licensed under CC BY 4.0. NCBI Bookshelf NBK570193. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support